Spero Therapeutics (SPRO) Announces Proposed 8M Share Common Offering

Spero Therapeutics (SPRO) PT Raised to $25 at Stifel, After Pharma Study Reults Published

Stifel analyst Stephen D. Willey raised the price target on Spero Therapeutics (NASDAQ: SPRO) to $25.00 (from $21.00) while maintaining a Buy rating.

Pre-Open Movers 09/08: (ALBO) (NKLA) (SPRO) Higher; (CRBP) (ACMR) (TSLA) Lower (more...)

Pre-Open Stock Movers:

Albireo Pharma Inc. (NASDAQ: ALBO) 79% HIGHER; announced positive topline results from PEDFIC 1, a global Phase 3 clinical trial evaluating the efficacy and safety of odevixibat and the largest study ever conducted in PFIC1 and PFIC2. PEDFIC 1 met its two primary endpoints, demonstrating that odevixibat reduced serum bile acid responses (sBAs) (p=0.003) and improved pruritus assessments (p=0.004) with a single digit diarrhea rate. Odevixibat is a highly potent, non-systemic ileal bile acid transport inhibitor (IBATi), for the treatment of progressive familial intrahepatic cholestasis (PFIC) patients.

Corbus Pharmaceuticals... More

Spero Therapeutics (SPRO) Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in cUTI and AP

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet medical need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Speros oral antibiotic candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). Topline data from the trial demonstrate that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with... More